Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1974 1
1982 1
1983 2
1986 2
1988 1
1989 4
1990 1
1991 1
1992 2
1994 1
1995 8
1996 3
1997 2
1998 1
1999 1
2000 3
2001 1
2002 3
2003 2
2004 6
2005 4
2006 3
2007 6
2008 3
2009 1
2010 5
2011 9
2012 3
2013 5
2014 4
2015 8
2016 6
2017 8
2018 2
2019 1
2020 5
2021 4
2022 5
2023 6

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. Ommen SR, et al. Circulation. 2020 Dec 22;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938. Epub 2020 Nov 20. Circulation. 2020. PMID: 33215938 Free article. Review.
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting do …
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorit …
Classification, Epidemiology, and Global Burden of Cardiomyopathies.
McKenna WJ, Maron BJ, Thiene G. McKenna WJ, et al. Circ Res. 2017 Sep 15;121(7):722-730. doi: 10.1161/CIRCRESAHA.117.309711. Circ Res. 2017. PMID: 28912179 Review.
In the past 25 years, major advances were achieved in the nosography of cardiomyopathies, influencing the definition and taxonomy of this important chapter of cardiovascular disease. ...Novel cardiomyopathies have been discovered (arrhythmogenic, restrictive, and noncompac …
In the past 25 years, major advances were achieved in the nosography of cardiomyopathies, influencing the definition and taxonomy of …
Noonan syndrome and clinically related disorders.
Tartaglia M, Gelb BD, Zenker M. Tartaglia M, et al. Best Pract Res Clin Endocrinol Metab. 2011 Feb;25(1):161-79. doi: 10.1016/j.beem.2010.09.002. Best Pract Res Clin Endocrinol Metab. 2011. PMID: 21396583 Free PMC article. Review.
Cardinal features include postnatally reduced growth, distinctive facial dysmorphism, congenital heart defects and hypertrophic cardiomyopathy, variable cognitive deficit and skeletal, ectodermal and hematologic anomalies. ...
Cardinal features include postnatally reduced growth, distinctive facial dysmorphism, congenital heart defects and hypertrophic ca …
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. Ommen SR, et al. Circulation. 2020 Dec 22;142(25):e558-e631. doi: 10.1161/CIR.0000000000000937. Epub 2020 Nov 20. Circulation. 2020. PMID: 33215931 Free article. Review. No abstract available.
Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature.
Bayonas-Ruiz A, Muñoz-Franco FM, Sabater-Molina M, Oliva-Sandoval MJ, Gimeno JR, Bonacasa B. Bayonas-Ruiz A, et al. ESC Heart Fail. 2023 Feb;10(1):8-23. doi: 10.1002/ehf2.14142. Epub 2022 Oct 1. ESC Heart Fail. 2023. PMID: 36181355 Free PMC article. Review.
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical characteristics of patients with hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: A systematic review and meta-analysis …
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical c …
Role of Exercise Testing in Hypertrophic Cardiomyopathy.
Rowin EJ, Maron BJ, Olivotto I, Maron MS. Rowin EJ, et al. JACC Cardiovasc Imaging. 2017 Nov;10(11):1374-1386. doi: 10.1016/j.jcmg.2017.07.016. JACC Cardiovasc Imaging. 2017. PMID: 29122139 Free article. Review.
Over the last 25 years, patients with hypertrophic cardiomyopathy (HCM) have been studied with a variety of methods employing physiological exercise that have made major contributions to disease management and are performed without increased risk. ...
Over the last 25 years, patients with hypertrophic cardiomyopathy (HCM) have been studied with a variety of methods emp …
Echocardiographic evaluation of hypertrophic cardiomyopathy: A review of up-to-date knowledge and practical tips.
Anwar AM, tenCate FJ. Anwar AM, et al. Echocardiography. 2021 Oct;38(10):1795-1808. doi: 10.1111/echo.15200. Epub 2021 Sep 23. Echocardiography. 2021. PMID: 34555207 Review.
Hypertrophic cardiomyopathy (HCM) is the most frequent cardiac disease with genetic substrate, affecting about .2%-.5% of the population. ...
Hypertrophic cardiomyopathy (HCM) is the most frequent cardiac disease with genetic substrate, affecting about .2%-.5% of the …
Sudden cardiac death in athletes: the Lausanne Recommendations.
Bille K, Figueiras D, Schamasch P, Kappenberger L, Brenner JI, Meijboom FJ, Meijboom EJ. Bille K, et al. Eur J Cardiovasc Prev Rehabil. 2006 Dec;13(6):859-75. doi: 10.1097/01.hjr.0000238397.50341.4a. Eur J Cardiovasc Prev Rehabil. 2006. PMID: 17143117 Review.
SCD was reported in almost all sports; most frequently involved were soccer (30%), basketball (25%) and running (15%). The PPSP were of varying quality and content. ...
SCD was reported in almost all sports; most frequently involved were soccer (30%), basketball (25%) and running (15%). The PPSP were …
Hypertrophic Cardiomyopathy and Pregnancy: A Retrospective Analysis From a Tertiary Care Hospital.
Sikka P, Suri V, Chopra S, Aggarwal N, Saha SC, Bansal R, Vijayvergiya R, Bahl A. Sikka P, et al. Tex Heart Inst J. 2022 Sep 1;49(5):e207427. doi: 10.14503/THIJ-20-7427. Tex Heart Inst J. 2022. PMID: 36223225 Free PMC article. Review.
Pregnancy in women with hypertrophic cardiomyopathy is not well described. In this retrospective study, we analyzed data on pregnant women with hypertrophic cardiomyopathy who were under follow-up care in the cardiology department of a tertiary care ho …
Pregnancy in women with hypertrophic cardiomyopathy is not well described. In this retrospective study, we analyzed data on pr …
Transthyretin Cardiac Amyloidosis.
Mankad AK, Shah KB. Mankad AK, et al. Curr Cardiol Rep. 2017 Aug 24;19(10):97. doi: 10.1007/s11886-017-0911-5. Curr Cardiol Rep. 2017. PMID: 28840452 Review.
PURPOSE OF REVIEW: Transthyretin (TTR)-related cardiac amyloidosis is a progressive infiltrative cardiomyopathy that mimics hypertensive, hypertrophic heart disease and may go undiagnosed. ...RECENT FINDINGS: Wild-type transthyretin (ATTRwt) protein causes cardiac a …
PURPOSE OF REVIEW: Transthyretin (TTR)-related cardiac amyloidosis is a progressive infiltrative cardiomyopathy that mimics hypertens …
125 results